City of Hope | Strategic Alliance Partners

Maurie Markman, MD, discusses the potential to shift the focus of cancer research towards the "real high technology of medicine", such as cancer vaccines.

Scientists transform genetic culprit behind treatment resistance into a skillful tool to use against cancer

Andreas M. Kaiser, MD, discusses the benefits of minimally invasive surgery for patients with colorectal cancer.

The evolution of biomedical research continues to pose quite thorny ethical dilemmas.

Preclinical data showed that mutated cells can persist for years without becoming cancer and require additional inflammatory push for malignancy to occur.

Yufei Liu, MD, PhD, discusses current radiation strategies, including SBRT and IMRT, along with the benefits of radiation therapy in colorectal cancer.

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Alan H. Bryce, MD, discusses treatment comparisons of ARPI efficacy according to disease volume and timing of metastasis development in mHSPC.

Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.

Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.

Andreas M. Kaiser, MD, discusses strategies to reduce postoperative complications and determine surgical eligibility in patients with CRC.

Ajay Goel, PhD, AGAF, discusses the potential utility of CA19-9 with an exosome-based liquid biopsy as a diagnostic biomarker in early-stage pancreatic cancer.

Andreas M. Kaiser, MD, discusses the differences between minimally invasive surgical approaches for colorectal cancer in community vs academic settings.

Tycel J. Phillips, MD, MPH, discusses the need for more large, randomized clinical trials enrolling patients with high-risk MCL.

Richard T. Lee, MD, discusses research showing the benefits of acupuncture, ginger, and ginseng for improving symptoms in patients with GI cancers.

Daneng Li, MD, discusses a trial evaluating casdozokitug plus atezolizumab and bevacizumab in unresectable, locally advanced or metastatic HCC.

Hedyeh Ebrahimi, MD, MPH, discusses clinical outcomes with CBM588 plus cabozantinib and nivolumab in metastatic renal cell carcinoma.

Charles B. Nguyen, MD, provides insight into current challenges faced in the non–clear cell RCC landscape beyond the NCCN’s recent guideline updates.

Amandeep Salhotra, MD, discusses data that have demonstrated the anti-GVHD activity of post-transplant Orca-Q in patients with hematologic malignancies.

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

Tycel Phillips, MD, MPH, discusses the rationale of the phase 1/2 NP30179 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Alexis LeVee, MD, discusses immune-related adverse effects in patients with early breast cancer treated with immune checkpoint inhibitors.

Drs Danilov and O'Brien discuss updates with acalabrutinib, zanubrutinib, and pirtobrutinib in CLL that were presented at the 2024 ASH Annual Meeting.

Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.

Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

Is it time to end the rhetoric that denies the benefit of antineoplastic pharmaceutical agents due to the absence of an OS improvement in a clinical trial?

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.

Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.